Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma
| Autor: | RICUPHAN KHAMKO, WIPHAWAN WASENANG, JUREERUT DADUANG, CHATRI SETTASATIAN, TEMDUANG LIMPAIBOON |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
Cancer Research Receptor Protein-Tyrosine Kinases GPI-Linked Proteins Prognosis Axl Receptor Tyrosine Kinase General Biochemistry Genetics and Molecular Biology Cholangiocarcinoma Bile Ducts Intrahepatic Bile Duct Neoplasms Proto-Oncogene Proteins Humans Cell Adhesion Molecules Research Article |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 |
| Popis: | Background/Aim: Cholangiocarcinoma (CCA) is a type of liver cancer originating from bile duct epithelium which has an unfavorable prognosis. Therefore, novel prognostic markers and effective therapeutic regimens are required. Opioid-binding protein/cell adhesion molecule-like (OPCML) is a tumor-suppressor protein that suppresses CCA cell proliferation via AXL receptor tyrosine kinase/signal transducer and activator of transcription 3 (AXL/STAT3) inactivation. However, this association in clinical samples remains unknown. We aimed to determine OPCML and AXL expression and investigate their association with clinicopathological features in patients with CCA. In addition, we also addressed whether OPCML enhanced the sensitivity of CCA cells to AXL inhibitor R428 in vitro. Materials and Methods: The expression of OPCML and AXL was determined by immunohistochemistry in 90 CCA tissue samples. The study of CCA cell line sensitivity to R428 was performed by cell viability assay. Results: The expression of OPCML was significantly lower while AXL expression was substantially higher in CCA than in adjacent normal tissue (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|